• Home
  • Search Results
  • Identification of salivary peptidomic biomarkers in chronic kidney disease patients undergoing haemodialysis.

Identification of salivary peptidomic biomarkers in chronic kidney disease patients undergoing haemodialysis.

Clinica chimica acta; international journal of clinical chemistry (2018-12-12)
Peiyuan Tong, Chao Yuan, Xiangyu Sun, Qi Yue, Xiaoling Wang, Shuguo Zheng

Chronic kidney disease (CKD) is a worldwide public health problem. To detect discriminating salivary peptide profiles between CKD patients undergoing haemodialysis (HD) and healthy controls (HCs) and to screen candidate biomarkers for CKD, we preliminarily explored the diagnostic potentiality of saliva. Saliva samples from 30 CKD HD patients and 35 HCs were analysed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) combined with weak cation exchange magnetic beads. Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was performed to identify the potential biomarkers. The HD group showed higher salivary pH. We chose 3 significantly different (p < 0.01) peptides to establish an effective discrimination model which was validated by a decision tree and ROC curve. Statistically significant correlations (p < 0.05) between the candidate salivary peptidomic biomarkers and serum parameters were found. Eight differentially expressed peptides were identified as segments of Histatin-1, Mucin-7, salivary acidic proline-rich phosphoprotein 1/2 (aPRP 1/2), submaxillary gland androgen-regulated protein 3B, and Histatin-3. Our findings substantiate the pivotal role of peptidomic methods in identifying biomarkers for CKD. Histatin-1, Mucin-7 and aPRP 1/2 are expected to be candidate salivary biomarkers of CKD HD patients. Furthermore, saliva might be a promising non-invasive diagnostic biofluid.

Product Number
Product Description

ProteoMass P14R MALDI-MS Standard, vial of 10 nmol

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.